1. Presti JC Jr. In: Tanagho EA, McAninch JW, editors. Neoplasm of the prostate gland. Smith's General Urology 2000;15th ed. New York: Lange Medical Books. 399–421.
2. Varenhorst E, Carlsson P, Pederson K. Clinical and economic considerations in the treatment of prostate cancer. Pharmaco Econ 1994;6:127–141.
3. Brawley OW, Kramer BS. In: Dawson NA, Vogelzang NJ, editors. The epidemiology and prevention of prostate cancer. Prostate Cancer 1994;New York: Wiley-Liss. 47–64.
4. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60–67.
5. Pu YS. Prostate cancer in Taiwan:epidemiology and risk factors. Int J Androl 2000;23:Suppl 2. 34–36.
6. Gu F. Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China. Chin Med J 2000;113:299–302.
7. Chang CK, Yu HJ, Chan KW, Lai MK. Secular trend and age-period-cohort analysis of prostate cancer mortality in Taiwan. J Urol 1997;158:1845–1848.
8. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 2002;90:174–178.
9. Sasagawa I, Nakada T. Epidemiology of prostatic cancer in east Asia. Ach Androl 2001;47:195–201.
11. Dohm G. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 1983;106:210–218.
12. Steinberg GN, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17:337–347.
13. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by genome wide scan. Science 1996;274:1371–1374.
14. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusshern D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998;20:175–179.
15. Wilson JMG. In: Bruce AW, Trachtenberg J, editors. Epidemiology of prostate cancer. Adenocarcinoma of the Prostate 1991;London: Springer-Verlag. 3–17.
16. Carter BS, Steinberg GD, Beaty TH, Childs B, Walsh PC. Familial risk factors for prostate cancer. Cancer Surv 1991;11:5–13.
17. Shibata A, Whittemore AS. Genetic predisposition to prostate cancer: Possible explanations for ethnic differences in risk. Prostate 1997;32:65–72.
18. Griffiths K, Morton MS, Denis LJ. Diet and Prostate Disease; An IPHC Teaching Programme 1996;Cardiff: Comp Graphics Services.
19. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999;161:152–155.
20. Akaza K, Stemmermann GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst 1973;50:1137–1144.
21. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995;87:652–661.
22. Ross RK, Bernstein L, Lobow RA, Shimizu H, Stanczyk FC, Pike MC. 5-alpha-reductase activity and the risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887–889.
23. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73–78.
24. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617–8623.
25. Rosenberg L, Palmer JR, Zeba AG, Warshauer ME, Stolley PD, Shapiro S. Vasectomy and the risk of prostate cancer. Am J Epidemiol 1990;132:1051–1055.